Literature DB >> 9499416

The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP.

D Smedley1, R Hamoudi, J Clark, W Warren, M Abdul-Rauf, G Somers, D Venter, K Fagan, C Cooper, J Shipley.   

Abstract

A recently described atypical myeloproliferative disorder is invariably associated with reciprocal translocations involving 8p11-12. The most common rearrangement is a t(8;13)(p11;q11-12). Here we determine that this translocation results in the fusion of the fibroblast growth factor receptor 1 gene (FGFR1), a member of the receptor tyrosine kinase family at 8p11, to a novel gene at 13q11-12 designated RAMP . The predicted RAMP protein exhibits strong homology to the product of a recently cloned candidate gene for X-linked mental retardation, DXS6673E . We also provide the first report of a novel, putative metal-binding motif, present as five tandem repeats in both RAMP and DXS6673E. RT-PCR detected only one of the two possible fusion transcripts, encoding a product in which the N-terminal 641 amino acids of RAMP become joined to the tyrosine kinase domain of FGFR1. Receptor tyrosine kinases are not commonly involved in the formation of tumour-specific fusion proteins. However, the previous reports of involvement of receptor tyrosine kinases in fusion proteins in non-Hodgkin's lymphoma, chronic myelomonocytic leukaemia and papillary thyroid carcinoma described similar rearrangements. By analogy with these, we propose that the RAMP-FGFR1 fusion product will contribute to progression of this myeloproliferative disorder by constitutive activation of tyrosine kinase function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9499416     DOI: 10.1093/hmg/7.4.637

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  13 in total

1.  ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5.

Authors:  D Smedley; A Demiroglu; M Abdul-Rauf; C Heath; C Cooper; J Shipley; N C Cross
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease.

Authors:  Chitta S Kasyapa; Padmaja Kunapuli; Lesleyann Hawthorn; John K Cowell
Journal:  Blood       Date:  2006-01-12       Impact factor: 22.113

3.  Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13).

Authors:  C Popovici; J Adélaïde; V Ollendorff; M Chaffanet; G Guasch; M Jacrot; D Leroux; D Birnbaum; M J Pébusque
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-12       Impact factor: 11.205

4.  8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways.

Authors:  G Guasch; V Ollendorff; J P Borg; D Birnbaum; M J Pébusque
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

5.  Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation.

Authors:  K C Hart; S C Robertson; D J Donoghue
Journal:  Mol Biol Cell       Date:  2001-04       Impact factor: 4.138

Review 6.  [The 8p11 myeloproliferative syndrome].

Authors:  A Reither; R Hehlmann; J M Goldman; N C Cross
Journal:  Med Klin (Munich)       Date:  1999-04-15

7.  Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

Authors:  Chitta Kasyapa; Ting-Lei Gu; Lalitha Nagarajan; Lalitha Natarajan; Roberto Polakiewicz; John K Cowell
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

8.  Avadomide induces degradation of ZMYM2 fusion oncoproteins in hematologic malignancies.

Authors:  Aline Renneville; Jessica A Gasser; Daniel E Grinshpun; Pierre M Jean Beltran; Namrata D Udeshi; Mary E Matyskiela; Thomas Clayton; Marie McConkey; Kaushik Viswanathan; Alexander Tepper; Andrew A Guirguis; Rob S Sellar; Sophie Cotteret; Christophe Marzac; Véronique Saada; Stéphane De Botton; Jean-Jacques Kiladjian; Jean-Michel Cayuela; Mark Rolfe; Philip P Chamberlain; Steven A Carr; Benjamin L Ebert
Journal:  Blood Cancer Discov       Date:  2021-03-10

9.  ZNF198 stabilizes the LSD1-CoREST-HDAC1 complex on chromatin through its MYM-type zinc fingers.

Authors:  Christian B Gocke; Hongtao Yu
Journal:  PLoS One       Date:  2008-09-22       Impact factor: 3.240

Review 10.  Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.

Authors:  Ayalew Tefferi
Journal:  J Cell Mol Med       Date:  2008-10-23       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.